Could AMAG Pharmaceuticals (AMAG) be worth $11 in the next year
What’s up with AMAG Pharmaceuticals?
AMAG Pharmaceuticals (AMAG) opened at $7.97, which means the stock is down 12.51% from yesterday’s closing price of 13.53. Today, the company has a high of $8.86 and a low of $7.61. The company has a market cap of $276.70 million with a 52-week high of $13.53 and a 52-week low of $4.41.
What about the future for AMAG Pharmaceuticals?
The high forecast for AMAG Pharmaceuticals is $11.00 while the low is $6.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. AMAG Pharmaceuticals has a strong forecast. A strong forecast is a result of strong earning reports as investors are willing to pay a higher share price today because of growth expectations in the future. Based on this information AMAG seems to be a safe buy.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.